KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other financing activities (2017 - 2025)

Aquestive Therapeutics (AQST) has 6 years of Other financing activities data on record, last reported at $7000.0 in Q3 2025.

  • For Q3 2025, Other financing activities fell 12.5% year-over-year to $7000.0; the TTM value through Sep 2025 reached $3000.0, up 100.04%, while the annual FY2023 figure was $4.6 million, N/A changed from the prior year.
  • Other financing activities reached $7000.0 in Q3 2025 per AQST's latest filing, down from $8000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $9.1 million in Q1 2023 and bottomed at -$7.9 million in Q4 2023.
  • Average Other financing activities over 3 years is $424000.0, with a median of $6000.0 recorded in 2025.
  • The widest YoY moves for Other financing activities: up 99.77% in 2024, down 99.94% in 2024.
  • A 3-year view of Other financing activities shows it stood at -$7.9 million in 2023, then soared by 99.77% to -$18000.0 in 2024, then skyrocketed by 138.89% to $7000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $7000.0 in Q3 2025, $8000.0 in Q2 2025, and $6000.0 in Q1 2025.